Mankind

Mankind Pharma launches “Angdaan Mahadaan” to inspire 1 crore Indians to pledge for organ donation A nationwide movement to turn awareness into action and encourage Indians to Pledge for organ donation as the ultimate gift of life. New Delhi, 2nd September 2026: In a step towards addressing India’s critical need for organ donors, Mankind Pharma Limited (“Mankind Pharma” or “Mankind”), one of India’s leading pharmaceutical companies, has launched its nationwide public awareness campaign “Angdaan Mahadaan”, with a goal of inspiring 1 Crore Indians to pledge for organ donation. The campaign was launched in the presence of transplant specialists and dignitaries from the National Organ and Tissue Transplant Organisation (NOTTO), who came together to raise public awareness, dispel myths and highlight the transformative impact of organ donation. Through “Angdaan Mahadaan”, Mankind Pharma aims to create greater awareness, address myths and misconceptions, and motivate millions of Indians to turn public awareness into meaningful action. Thousands of patients are waiting for life-saving organ transplants. For many, an organ transplant is the only chance to survive or live a healthier life. Unfortunately, the demand for organs far exceeds the number of available donors. By choosing to become an organ donor, you can offer hope, restore health, and give someone a second chance at life. The initiative seeks to take the conversation around organ donation beyond hospitals and healthcare institutions and into homes, families and communities across India, encouraging people to make a conscious decision today that could give someone a second chance at life. The campaign was launched at an Organ Donation Awareness Event hosted by Mankind Pharma, engaging more than 25,000 Mankindians, their families and extended communities. The event featured sessions on the realities of organ donation, myths and facts surrounding transplantation, and the current organ donation landscape in India. The event brought together Dr. D.S. Ray, Chief Nephrologist and Head, Renal Transplant Programme, R N Tagore International Institute of Cardiac Sciences, Narayana Health, Kolkata; Dr. Abhideep Chaudhary, Chairman and HOD, HPB Surgery and Liver Transplantation, BLK-Max Super Speciality Hospital, New Delhi; and Dr. Kanika Rastogi, National Organ and Tissue Transplant Organisation (NOTTO), New Delhi to raise public awareness about the importance of organ donation. “To give is to live beyond yourself. Through Angdaan Mahadaan, we want to inspire people across India to recognise the extraordinary power of a simple decision: the decision to give someone another chance at life. Our ambition is to motivate 1 crore Indians to pledge for organ donation and make this a movement that creates a lasting legacy of hope,” said Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma Ltd. The campaign encourages every Indian to take a simple but powerful step: pledge to donate organs and inspire others to do the same. The ambition is clear: 1 crore pledges, 1 crore acts of hope and a nationwide movement to give life. Indians can register their pledge through the National Organ and Tissue Transplant Organisation (NOTTO) at https://notto.mohfw.gov.in/donor-pledge Through “Angdaan Mahadaan”, Mankind Pharma aims to build a culture where organ donation becomes a conversation in every home and a conscious choice for every individual, because the greatest gift we can leave behind is not what we own, but by pledging to become an organ donor today we can Live Beyond our Life. Angdaan Mahadaan: Pledge. Inspire. Save Lives. About Mankind Pharma Limited Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists.